Ann: ATL1102 Revised Plans accelerate reporting of unblinded data, page-58

Your question had nothing to do with Sarepta

You asked me a question and i answered it

but being as you have fetched Sarepta up

I would sooner go into a parenting conversation with $90mil les expenses having completed a pivotal trial knowing i was going to market

Rather than going into talks with further trials to complete less cash and a boat load of potential

Im not saying that is what is going to happen to us, but did you not read or listen they have more chance of partnering once Data is in

But the direction we are now headed is not pivotal it isn't the end game

The end game now is to show results in comparison or better to our previous trial to move forwards

I thought thats what the last trial was all about

Charmaine was asked the question how long to market,now we are going down this route and honestly she could not answer and said so ,so just exactly how far away are we now from marketing approval

Before yes things may have been delayed but the end game all things considered was definitive

Marketing approval should the trial be a success

Anyway Ryn i wont go on with it each to their own, i know my own DD i try to share factual information along with my views take them as you see fit

all good